The effect of Insulin Degludec on glycemic control in diabetic cats over a 12-month period

• Published in: Journal of Veterinary Medical Science Vol. 82; no. 6; pp. 695 - 698
• Main Authors: ODA, Hitomi, MORI, Akihiro, SAKO, Toshinori
• Format: Journal Article
• Language: English
• Published: Japan JAPANESE SOCIETY OF VETERINARY SCIENCE 2020; Japan Science and Technology Agency; The Japanese Society of Veterinary Science
• Subjects: Animals; Body weight; Cat Diseases - drug therapy; Cats; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - veterinary; Dosage; feline; Female; glucose lowering effect; Glycemic Control - veterinary; Hypoglycemic Agents - therapeutic use; Insulin; Insulin, Long-Acting - therapeutic use; Internal Medicine; Male; Serum Albumin - metabolism; ultra-long-acting insulin; glucose lowering effect; ultra-long-acting insulin; feline; diabetes
• ISSN: 0916-7250; 1347-7439; 1347-7439
• DOI: 10.1292/jvms.19-0309

Insulin degludec (IDeg) is a long-acting basal insulin recently developed for use in humans. This study aimed to investigate the effects of IDeg on glycemic control in diabetic cats. Changes in body weight, IDeg dosage, and glycated albumin (GA) were evaluated at 0, 1, 3, 6, 9, and 12 months following initiation of IDeg. A significant decrease in GA was observed and a mean GA level below 25% was achieved between 3 and 12 months. Furthermore, a significant increase in body weight was observed between 3 and 12 months. The mean IDeg dose was 0.75 ± 0.68 IU/kg/day at 12 months. Taken together, long-term glycemic control was successfully achieved in diabetic cats using IDeg.